MedTrace Logo

Palbociclib + Ganitumab In Ewing Sarcoma

NCT04129151 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-08-01

Study results available
· View outcomes & findings →

Summary

This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma.

The names of the study drugs involved in this study are:

* Palbociclib
* Ganitumab

Conditions

  • Ewing Sarcoma
  • Ewing's Sarcoma Recurrent

Interventions

DRUG

Palbociclib

Oral, per protocol pre determined dosage, once a day for 21 days

DRUG

Ganitumab

-Intravenous, per protocol predetermined dosage, twice per cycle

Sponsors & Collaborators

  • 1 Million 4 Anna Foundation

    collaborator OTHER

  • Carson Sarcoma Foundation

    collaborator OTHER

  • Teaming up to Fight Childhood Cancer

    collaborator OTHER

  • ChemoWarrior: the eli sidler foundation

    collaborator UNKNOWN

  • i-ROK Foundation

    collaborator OTHER

  • Rutledge Cancer Foundation

    collaborator OTHER

  • Alan B. Slifka Foundation

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • David Shulman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2022-12-15
Completion
2022-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129151 on ClinicalTrials.gov